Evidence map›Paper›PMID 27519049›Full record

ArticlePloS one2016

Deficiency and Also Transgenic Overexpression of Timp-3 Both Lead to Compromised Bone Mass and Architecture In Vivo.

Behzad Javaheri, Mark Hopkinson, Blandine Poulet, Andrea S Pollard, Sandra J Shefelbine, Yu-Mei Chang, Philippa Francis-West, George Bou-Gharios, Andrew A Pitsillides

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Single Cell RNA Sequencing Reveals Critical Functions ofFrontiers in cell and developmental biology · 2022
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Behzad JavaheriDepartment of Comparative Biomedical Sciences, The Royal Veterinary College, London, United Kingdom.ORCID http://orcid.org/0000-0001-7941-3104
Mark HopkinsonDepartment of Comparative Biomedical Sciences, The Royal Veterinary College, London, United Kingdom.
Blandine PouletInstitute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.
Andrea S PollardDepartment of Comparative Biomedical Sciences, The Royal Veterinary College, London, United Kingdom.
Sandra J ShefelbineDepartment of Mechanical and Industrial Engineering, Northeastern University, Boston, Massachusetts, United States of America.
Yu-Mei ChangDepartment of Comparative Biomedical Sciences, The Royal Veterinary College, London, United Kingdom.
Philippa Francis-WestDepartment of Craniofacial Development and Stem Cell Biology, King's College London, London, United Kingdom.
George Bou-GhariosInstitute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.
Andrew A PitsillidesDepartment of Comparative Biomedical Sciences, The Royal Veterinary College, London, United Kingdom.
Royal Veterinary College · GBUniversity of Liverpool · GBKing's College London · GBNortheastern University · US

Funding

Arthritis Research UK 20413Versus Arthritis 20039Versus Arthritis 20581Versus Arthritis 20859
6 · The paper itself

Abstract

Tissue inhibitor of metalloproteinases-3 (TIMP-3) regulates extracellular matrix via its inhibition of matrix metalloproteinases and membrane-bound sheddases. Timp-3 is expressed at multiple sites of extensive tissue remodelling. This extends to bone where its role, however, remains largely unresolved. In this study, we have used Micro-CT to assess bone mass and architecture, histological and histochemical evaluation to characterise the skeletal phenotype of Timp-3 KO mice and have complemented this by also examining similar indices in mice harbouring a Timp-3 transgene driven via a Col-2a-driven promoter to specifically target overexpression to chondrocytes. Our data show that Timp-3 deficiency compromises tibial bone mass and structure in both cortical and trabecular compartments, with corresponding increases in osteoclasts. Transgenic overexpression also generates defects in tibial structure predominantly in the cortical bone along the entire shaft without significant increases in osteoclasts. These alterations in cortical mass significantly compromise predicted tibial load-bearing resistance to torsion in both genotypes. Neither Timp-3 KO nor transgenic mouse growth plates are significantly affected. The impact of Timp-3 deficiency and of transgenic overexpression extends to produce modification in craniofacial bones of both endochondral and intramembranous origins. These data indicate that the levels of Timp-3 are crucial in the attainment of functionally-appropriate bone mass and architecture and that this arises from chondrogenic and osteogenic lineages.

Indexed as

Bone DensityAnimalsCancellous BoneChondrocytesFemaleMatrix MetalloproteinasesMiceMice, Inbred C57BLMice, Inbred CBAMice, KnockoutMice, TransgenicOsteogenesisTissue Inhibitor of Metalloproteinase-3Matrix MetalloproteinasesTIMP3 protein, humanTissue Inhibitor of Metalloproteinase-3

Identifiers

PMID27519049
PMCPMC4982603
OpenAlexW2517267670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.